Suppr超能文献

涉及 P-糖蛋白(一种外排转运蛋白)的心血管药物的药物相互作用研究对口服 Xa 因子抑制剂依度沙班的药代动力学的影响。

Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.

机构信息

Daiichi Sankyo Pharma Development, 399 Thornall Street, Edison, NJ, 08837, USA,

出版信息

Am J Cardiovasc Drugs. 2013 Oct;13(5):331-42. doi: 10.1007/s40256-013-0029-0.

Abstract

BACKGROUND

Edoxaban, an oral direct factor Xa inhibitor, is in development for thromboprophylaxis, including prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). P-glycoprotein (P-gp), an efflux transporter, modulates absorption and excretion of xenobiotics. Edoxaban is a P-gp substrate, and several cardiovascular (CV) drugs have the potential to inhibit P-gp and increase drug exposure.

OBJECTIVE

To assess the potential pharmacokinetic interactions of edoxaban and 6 cardiovascular drugs used in the management of AF and known P-gp substrates/inhibitors.

METHODS

Drug-drug interaction studies with edoxaban and CV drugs with known P-gp substrate/inhibitor potential were conducted in healthy subjects. In 4 crossover, 2-period, 2-treatment studies, subjects received edoxaban 60 mg alone and coadministered with quinidine 300 mg (n = 42), verapamil 240 mg (n = 34), atorvastatin 80 mg (n = 32), or dronedarone 400 mg (n = 34). Additionally, edoxaban 60 mg alone and coadministered with amiodarone 400 mg (n = 30) or digoxin 0.25 mg (n = 48) was evaluated in a single-sequence study and 2-cohort study, respectively.

RESULTS

Edoxaban exposure measured as area under the curve increased for concomitant administration of edoxaban with quinidine (76.7 %), verapamil (52.7 %), amiodarone (39.8 %), and dronedarone (84.5 %), and exposure measured as 24-h concentrations for quinidine (11.8 %), verapamil (29.1 %), and dronedarone (157.6 %) also increased. Administration of edoxaban with amiodarone decreased the 24-h concentration for edoxaban by 25.7 %. Concomitant administration with digoxin or atorvastatin had minimal effects on edoxaban exposure.

CONCLUSION

Coadministration of the P-gp inhibitors quinidine, verapamil, and dronedarone increased edoxaban exposure. Modest/minimal effects were observed for amiodarone, atorvastatin, and digoxin.

摘要

背景

依度沙班是一种口服直接因子 Xa 抑制剂,目前正在开发用于血栓预防,包括预防房颤(AF)患者的中风和全身性栓塞。P-糖蛋白(P-gp)是一种外排转运蛋白,调节外源性物质的吸收和排泄。依度沙班是 P-gp 的底物,几种心血管(CV)药物具有抑制 P-gp 和增加药物暴露的潜力。

目的

评估依度沙班与 6 种用于 AF 管理且已知为 P-gp 底物/抑制剂的心血管药物之间潜在的药代动力学相互作用。

方法

在健康受试者中进行了依度沙班与具有已知 P-gp 底物/抑制剂潜力的 CV 药物的药物相互作用研究。在 4 项交叉、2 期、2 治疗研究中,受试者单独接受依度沙班 60mg 治疗,或同时给予奎尼丁 300mg(n=42)、维拉帕米 240mg(n=34)、阿托伐他汀 80mg(n=32)或决奈达隆 400mg(n=34)。此外,在一项单序列研究和两项队列研究中,分别评估了依度沙班 60mg 与胺碘酮 400mg(n=30)或地高辛 0.25mg(n=48)同时给药。

结果

依度沙班的暴露程度(曲线下面积)增加,同时给予依度沙班与奎尼丁(76.7%)、维拉帕米(52.7%)、胺碘酮(39.8%)和决奈达隆(84.5%),同时给予依度沙班与奎尼丁(11.8%)、维拉帕米(29.1%)和决奈达隆(157.6%)的 24 小时浓度也增加。依度沙班与胺碘酮合用使依度沙班的 24 小时浓度降低 25.7%。与地高辛或阿托伐他汀合用对依度沙班的暴露影响很小。

结论

P-gp 抑制剂奎尼丁、维拉帕米和决奈达隆与依度沙班合用可增加依度沙班的暴露。胺碘酮、阿托伐他汀和地高辛的影响较小。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3368/3781304/f8c01488a184/40256_2013_29_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验